RNU6-1308P

Across TCGA pan-cancer cohorts, RNU6-1308P RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNU6-1308P data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RNU6-1308P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-1308P expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

BLCA, KIRC, and PAAD are the cancer types where RNU6-1308P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Tertile	All	0.074	0.720	<.001	144	view →
KIRC	DFS	Tertile	III,IV	0.188	0.665	<.001	72	view →
PAAD	OS	Tertile	All	0.263	0.594	.020	36	view →
STAD	OS	Tertile	IV	1.000	0.309	.034	30	view →
OV	DFS	Tertile	IV	0.100	0.464	.044	18	view →
ESCA	OS	Tertile	III,IV	1.000	0.368	.024	18	view →
THCA	DFS	Tertile	III,IV	0.145	0.825	<.001	18	view →
LAML	DFS	Tertile	All	0.112	0.582	.010	18	view →
SARC	OS	Tertile	All	0.252	0.771	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

RNU6-1308P–BLCA (OS)

Open the BLCA breakdown →